THE FIRST QUALITY-RELATED DEVICE 'CLOSE-OUT' LETTER was sent by FDA to manufacturer Z-Medica on March 1, officially closing out a December 2009 warning letter that cited the firm for four violations of the Quality System Regulation. Z-Medica's close-out letter came surprisingly fast, given initial expectations from CDRH's Office of Compliance that close-outs could take up to a year. How quickly future close-out letters are issued depends on the specific violations and whether a follow-up inspection is needed, said Larry Spears, deputy director of regulatory affairs in the compliance office. Attorneys debate whether Z-Medica deserved the close-out letter and whether the contents were sufficient. Z-Medica explains how it fixed its quality problems and gained resolution with FDA in less than five months
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.
Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
